Lauren classification and individualized chemotherapy in gastric cancer (Review)

被引:160
作者
Ma, Junli [1 ,2 ]
Shen, Hong [2 ,3 ]
Kapesa, Linda [1 ]
Zeng, Shan [1 ,2 ]
机构
[1] Cent S Univ, Xiangya Hosp, Dept Oncol, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China
[2] Cent S Univ, Xiangya Hosp, Key Lab Mol Radiat Oncol, Changsha 410008, Hunan, Peoples R China
[3] Cent S Univ, Xiangya Hosp, Inst Med Sci, Changsha 410008, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
gastric cancer; Lauren classification; intestinal type; diffuse type; individualized chemotherapy; HELICOBACTER-PYLORI ERADICATION; INDEPENDENT PROGNOSTIC-FACTOR; E-CADHERIN; INTESTINAL METAPLASIA; MICROSATELLITE INSTABILITY; DNA METHYLATION; DIFFUSE; EXPRESSION; CARCINOMA; GENE;
D O I
10.3892/ol.2016.4337
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastric cancer is one of the most common malignancies worldwide. During the last 50 years, the histological classification of gastric carcinoma has been largely based on Lauren's criteria, in which gastric cancer is classified into two major histological subtypes, namely intestinal type and diffuse type adenocarcinoma. This classification was introduced in 1965, and remains currently widely accepted and employed, since it constitutes a simple and robust classification approach. The two histological subtypes of gastric cancer proposed by the Lauren classification exhibit a number of distinct clinical and molecular characteristics, including histogenesis, cell differentiation, epidemiology, etiology, carcinogenesis, biological behaviors and prognosis. Gastric cancer exhibits varied sensitivity to chemotherapy drugs and significant heterogeneity; therefore, the disease may be a target for individualized therapy. The Lauren classification may provide the basis for individualized treatment for advanced gastric cancer, which is increasingly gaining attention in the scientific field. However, few studies have investigated individualized treatment that is guided by pathological classification. The aim of the current review is to analyze the two major histological subtypes of gastric cancer, as proposed by the Lauren classification, and to discuss the implications of this for personalized chemotherapy.
引用
收藏
页码:2959 / 2964
页数:6
相关论文
共 82 条
[51]   Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis [J].
Mizoshita, T ;
Tsukamoto, T ;
Nakanishi, H ;
Inada, K ;
Ogasawara, N ;
Joh, T ;
Itoh, M ;
Yamamura, Y ;
Tatematsu, M .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (12) :727-734
[52]   Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) [J].
Narahara, Hiroyuki ;
Iishi, Hiroyasu ;
Imamura, Hiroshi ;
Tsuburaya, Akira ;
Chin, Keisho ;
Imamoto, Haruhiko ;
Esaki, Taito ;
Furukawa, Hiroshi ;
Hamada, Chikuma ;
Sakata, Yuh .
GASTRIC CANCER, 2011, 14 (01) :72-80
[53]   Helicobacter pylori and molecular events in precancerous gastric lesions [J].
Nardone, G ;
Rocco, A ;
Malfertheiner, P .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (03) :261-270
[54]   Familial gastric cancer: genetic susceptibility, pathology, and implications for management [J].
Oliveira, Carla ;
Pinheiro, Hugo ;
Figueiredo, Joana ;
Seruca, Raquel ;
Carneiro, Fatima .
LANCET ONCOLOGY, 2015, 16 (02) :E60-E70
[55]   Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy [J].
Palestro, Giorgio ;
Pellicano, Rinaldo ;
Fronda, Gian Ruggero ;
Valente, Guido ;
De Giuli, Marco ;
Soldati, Tito ;
Pugliese, Agostino ;
Taraglio, Stefano ;
Garino, Mauro ;
Campra, Donata ;
Cutufia, Miguel Angel ;
Margaria, Elena ;
Spinzi, Giancarlo ;
Ferrara, Aldo ;
Marenco, Giorgio ;
Rizzetto, Mario ;
Ponzetto, Antonio .
WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (45) :7131-7135
[56]   HER-2/neu amplification is an independent prognostic factor in gastric cancer [J].
Park, Dong Il ;
Yun, Jung Won ;
Park, Jung Ho ;
Oh, Suk Joong ;
Kim, Hong Joo ;
Cho, Yong Kyun ;
Il Sohn, Chong ;
Jeon, Woo Kyu ;
Kim, Byung Ik ;
Yoo, Chang Hak ;
Son, Byung Ho ;
Cho, Eun Yoon ;
Chae, Seoung Wan ;
Kim, Eo-Jin ;
Sohn, Jin Hee ;
Ryu, Seung Ho ;
Sepulveda, Antonia R. .
DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (08) :1371-1379
[57]   CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients [J].
Park, S. R. ;
Kong, S-Y ;
Nam, B-H ;
Choi, I. J. ;
Kim, C. G. ;
Lee, J. Y. ;
Cho, S. J. ;
Kim, Y. W. ;
Ryu, K. W. ;
Lee, J. H. ;
Rhee, J. ;
Park, Y-I ;
Kim, N. K. .
BRITISH JOURNAL OF CANCER, 2011, 104 (07) :1126-1134
[58]  
Patru CL, 2013, MED-SURG J, V117, P199
[59]  
Pereyra Lisandro, 2011, Acta Gastroenterol Latinoam, V41, P142
[60]   Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China [J].
Qiu, Miao-zhen ;
Cai, Mu-yan ;
Zhang, Dong-sheng ;
Wang, Zhi-qiang ;
Wang, De-shen ;
Li, Yu-hong ;
Xu, Rui-hua .
JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11